A Phase Ib Multicenter Dose-Finding and Safety Study of Venetoclax and Obinutuzumab in Patients With Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2019
At a glance
- Drugs Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Genentech
- 12 Mar 2019 Results published in the Blood
- 05 Mar 2019 Planned End Date changed from 15 Dec 2018 to 30 Mar 2019.
- 05 Mar 2019 Planned primary completion date changed from 15 Dec 2018 to 30 Mar 2019.